Drugs / 23ME-01473
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06290388 | Mar → Nov 2024 | cancer | 23andMe, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23ME-01473 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06290388 ↗ |
| Route | Intravenous | “23Me-01473 given by intravenous infusion” NCT06290388 ↗ |